Clinical trial NCT04186247: Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Official title: Personalized AZithromycin/metronidAZole, in Combination With Standard Induction Therapy, to Achieve a Fecal Microbiome Community Structure and Metagenome Changes Associated With Sustained Remission in Pediatric Crohn's Disease (CD): a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Crohn Disease
Pediatric Crohns Disease
Keywords: Microbiome
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: Crohn's and Colitis Foundation
name: University of Amsterdam
First posted: 2019-12-04
Enrollment: 12
Sex: ALL
Minimum age (years): 3
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-center, randomized, controlled open-label add-on design trial pilot study to evaluate the efficacy of personalized adjunctive antibiotic (azithromycin + metronidazole) therapy in pediatric subjects with mild to moderate Crohn's disease (CD) who have a microbiome profile associated with increased risk of early relapse. This an add-on design trial for subjects already receiving standard of care therapy to induce remission; there will be no placebos.

Detailed description: The study hypothesis is that adjunctive antibiotic therapy will improve clinical response to standard of care (SOC) induction therapy in a subgroup of CD patients with a relapse-associated microbiome profile.

Prior to starting SOC induction therapy at week 0, subjects will provide a baseline stool sample that will be screened for microbiome profiles associated with risk of relapse according to an established statistical model.

At week 4, subjects with a relapse-associated microbiome will be randomized into either a control arm that will continue to receive SOC induction therapy for an additional 8 weeks, or a treatment arm that will receive adjunctive antibiotic therapy in addition to continuing to receive SOC induction therapy for an additional 8 weeks. Subjects who do not have a relapse-associated microbiome will enter a separate control arm that will continue to receive SOC induction therapy and will have data collected for exploratory objectives. Subjects who are not in clinical remission by week 4 will receive antibiotic therapy regardless of microbiome signature at baseline. Subjects will be monitored for an additional 40 weeks after the treatment period (52 weeks total).

Eligibility criteria: Inclusion Criteria:

1. Provision of signed and dated informed consent form (and assent form, as applicable);
2. Stated willingness to comply with all study procedures and availability for the duration of the study;
3. Male or female, aged 3 to 17 years;
4. Diagnosed with CD according to standard clinical and histological criteria, within 36 months of week 0;
5. Exhibiting mild to moderate symptoms of active disease, as determined by a PCDAI score \>10 (or \> 7.5 excluding the height item) and ≤37.5;
6. Fecal calprotectin level \>=250 µg/g within 30 days prior to week 0 visit based on local measurement, if available, or to be arranged with lead site if an endoscopy is not performed within 30 days prior to week 0 visit.

Exclusion Criteria:

1. Current or previous use of biologic therapy;
2. Presence of stricturing, penetrating (intestinal or perianal) and/or fistulizing CD;
3. Pregnancy or lactation;
4. Have undergone intestinal resection;
5. Positive Clostridium Difficile toxin;
6. Treatment with another investigational drug or other intervention within 30 days before week 0;
7. Risk factors for arrhythmia including history of prolonged corrected QT interval (QTc), hypokalemia or hypomagnesemia, resting bradycardia, or concurrent treatment with other drugs with potential for QT prolongation;
8. History of cockayne syndrome;
9. Prior diagnosis of any hematologic condition/blood dyscrasia which may result in leukopenia (even if leukocyte count is normal at screening);
10. Known allergy or intolerance to azithromycin or metronidazole;
11. Subjects who received intravenous anti-infective within 35 days prior to week 0 visit or anti-infectives within 14 days prior to the week 0 visit;
12. Subject on oral aminosalicylates who has not been on stable doses for greater than, or discontinued within, at least 14 days prior to week 0;
13. Subject on cyclosporine, tacrolimus or mycophenolate mofetil. Stable doses (no change within 14 days prior to week 0) of azathioprine, 6-mercaptopurine or methotrexate (MTX) are not a reason for exclusion;
14. Subject who received fecal microbial transplantation within 35 days prior to week 0 visit;
15. Screening laboratory and other analyses show any of the following abnormal results:

    * aspartate transaminase (AST), alanine transaminase (ALT) \> 2 X upper limit of the reference range,
    * White blood cell (WBC) count \< 3.0 X 109/L,
    * Total bilirubin \>= 20 micromol/liter (1.17 mg/dL); except for subjects with isolated elevation of indirect bilirubin relating to Gilbert syndrome,
    * Estimated glomerular filtration rate (GFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula of \< 30 mL/min/1.73 m²,
    * Hemoglobin \< 80 gram/liter,
    * Platelets \< 100,000/µL.

Primary outcomes:
measure: Percent of Subjects with Sustained Remission
timeFrame: Week 52
measure: Feasibility of multinational microbiome-randomized trial
timeFrame: week 52
Secondary outcomes:
measure: Change in Pediatric Crohn's Disease Activity Index (PCDAI) Score over Baseline to Week 52
timeFrame: Baseline to Week 52
measure: Change in Fecal Calprotectin Levels in Stool over Baseline to Week 52
timeFrame: Baseline to Week 52
measure: Change in C-Reactive Protein (CRP) Levels in Blood over Baseline to Week 52
timeFrame: Baseline to Week 52
measure: Change in IMPACT-III Score over Baseline to Week 52
timeFrame: Baseline to Week 52
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UCSF Benioff Children's Hospital
state: California
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh
state: Pennsylvania
city: Halifax
country: Canada
facility: IWK Health Centre
city: Tel Aviv
country: Israel
facility: Wolfson Medical Centre
city: Amsterdam
country: Netherlands
facility: Amsterdam UMC
Study officials:
affiliation: Amsterdam UMC
name: Johan E Van Limbergen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Edith Wolfson Medical Centre, Tel Aviv
name: Arie Levine, MD
role: STUDY_CHAIR
affiliation: University North Carolina
name: Francisco Sylvester, MD
role: STUDY_CHAIR
References: